Managing Young People With ADHD in Primary Care Study

NCT ID: NCT05518435

Last Updated: 2024-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

816 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-28

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Attention deficit hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. It affects around 5% of children and adolescents, and up to 40% continue to experience symptoms into adulthood. Primary care practitioners (e.g., general practitioners (GPs), nurses, link workers, clinical pharmacists) play an important role in the healthcare of young people (YP) with ADHD, particularly due to long waiting times in adult mental health services, and patchy provision of specialist services. However, many practitioners feel unsure about how to support YP at this vulnerable stage in their lives. Practitioners report concerns about prescribing ADHD medication and a desire for more guidance. Currently, little is known about how YP with ADHD are supported in primary care, the strengths and weakness of existing care pathways, and how care can be improved.

Aims:

To provide an evidence-base by mapping current services, and co-produce guidance to improve and better co-ordinate primary care for YP aged 16-25 with ADHD.

Methods:

Three interlinked studies. A mapping study including a national survey of stakeholders to map patient pathways, prescribing practice, shared-care arrangements, and practitioner roles. A qualitative study including semi-structured interviews with YP and practitioners, to gain insight into experiences of 'what works' and 'what is needed'. Workshops to co-develop a map of patient pathways, key messages, and clinical guidance.

Patient Involvement:

This research has been developed in response to identified gaps in services, and requests from people with ADHD. The team includes young people with ADHD whose input will help ensure the research is sensitive and relevant, and an academic GP to ensure identified solutions are deliverable within primary care settings.

Impact:

The expected impact of this research is improvement of the quality and experience of care for YP with ADHD. Also, to improve experiences of primary care providers facing difficulties managing ADHD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research aims to map current services and co-create evidence-based guidance to improve and better co-ordinate primary care for young people aged 16-25 years with ADHD.

OBJECTIVES

The objectives of this research are to:

1. Develop a national map and overview of current primary care pathways and prescribing practice in the management of young people with ADHD
2. Explore:

1. Primary care providers and related organisations' needs for information resources and prescribing support in their roles managing care for young people with ADHD
2. The expectations and needs of young people aged 16-25 regarding primary care ADHD support, information, and management
3. Co-produce evidence informed guidance to better co-ordinate primary care for young people with ADHD, based on discussions around findings from objectives 1, 2a and 2b

OUTCOMES

The outcomes of this research will be shaped by close work with professionals and members of the community, via the practice and policy research advisory group (P-RAG) and young person and parent/carer research advisory group (Y-RAG) groups, to ensure their relevance and utility. Anticipated outcomes include:

1. National overview of primary care provision for young people with ADHD across England, including:

1. Geographic map, showing variation in provision by NHS region or appropriate organisational boundaries
2. Summary of existing care pathways for the management of young people with ADHD in primary care, including exemplars of best practice
2. Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care including:

1. Health professionals' needs for information resources and prescribing support
2. Young people with ADHD and their parent/carers' needs for information resources, healthcare, and support with self-management
3. Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD.

STUDY DESIGN and METHODS Overview: This mixed methods study consists of three work packages. Each WP involves data collection/creation working with the following stakeholder groups.

* Patients, with a focus on young people (aged 16-25) with ADHD, and their parent/carers
* Health professionals, with a focus on those in primary care (including general practitioners (GPs), specialist nurses, mental health practitioners, and clinical pharmacists)
* Commissioners/providers of NHS healthcare for people with ADHD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Work package 1 (WP1) - survey

WP1 aims to recruit a minimum of 252 survey respondents, providing a minimum of six responses for each of the 42 Integrated Care Systems (ICSs) in England. The aim will be to gather responses from as many respondents as possible, to provide as much information as possible on primary care provision across over \>1200 PCNs in England. This will provide the first national overview of prescribing practice and the availability of health care for young people with ADHD through primary care in England. The inclusion of three stakeholder groups (health professional, service users, and commissioners/providers) will ensure that the survey includes reports from a balance of perspectives and provide the opportunity to compare data between groups and locations.

The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision.

None, observational study

Intervention Type OTHER

The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Work package 2 (WP2) - qualitative study

WP2 aims to recruit between 20 and 30 participants, consisting of 10-15 young people (aged 16-25) with ADHD and their parent carers and 10-15 health professionals and commissioners/providers. Participants will be recruited from between three and six geographic locations (e.g., PCNs), dependent on findings from WP1. This sample size will enable qualitative data to be collected from approximately five participants per location.

The sampling frame for WP2 consists of a purposive selection of stakeholders.

None, observational study

Intervention Type OTHER

The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Work package 3 (WP3) - co-production of guidance

WP3 aims to recruit between six and 16 participants, consisting of 2-6 young people (aged 16-25) with ADHD and/or their parents/carers, 2-6 health professional and/or commissioners/providers, and between 1 and 4 members of the research team. The sample will be sufficient to include perspectives from identified key stakeholders, while the relatively small group size will support close group work. The small sample size will also enable delivery of key features of co-production research such as building strong relationships and providing opportunities for growth and development of participants.

The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers.

None, observational study

Intervention Type OTHER

The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

None, observational study

The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Self-identifies as

* Being at least one of the following:

* A person aged 16 or over with lived experience of ADHD, or parent/carer of a person with ADHD
* Health professional (person working in any role that provides healthcare services, include NHS, voluntary and private services, clinical, managerial, leadership and administrative roles)
* Commissioner/provider of National Health Service (NHS) healthcare services (e.g., member of clinical commissioning group, primary care network (PCN), integrated care system (ICS), or another NHS organisation)
* Currently resident, working, or studying in England


* One of the following:

* Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD
* Health professional (person that provides healthcare services with a focus on primary care, including clinical, managerial, leadership and administrative roles)
* Commissioner/provider of healthcare services (e.g., member of clinical commissioning group, PCN, ICS, NHS, or another organisation)
* Currently resident or working in England
* Currently resident or working close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1)


* One of the following:

* Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD
* Health professional (person that provides healthcare services, including clinical, managerial, leadership and administrative roles)
* Commissioner/provider of NHS healthcare services (e.g., member of clinical commissioning group, PCN, ICS, local authority, or another NHS organisation)
* A member of the MAP study research team
* Currently resident, working, or studying in England
* Willing and able to work collaboratively and engage in consultations to co-produce evidence-based guidance for improving the co-ordination of primary care for young people with ADHD

Exclusion Criteria

* Does not identify as a person aged 16 or over with lived experience of ADHD, a health professional, or a commissioner/provider of NHS health services
* Not currently resident, working, or studying in England

WP2 QUALITATIVE STUDY


* Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, or commissioner/provider of health services
* Not currently resident or working in England
* Not currently resident, working, or studying close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1)

WP3 Co-PRODUCTION


* Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, commissioner/provider of NHS health services, or a member of the MAP study research team
* Not currently resident, working, or studying in England
* Not willing and able to work collaboratively and engage in consultations to co-produce evidence-based guidance for improving the co-ordination of primary care for young people with ADHD
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Exeter

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Price, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Exeter Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anna Price

Exeter, Devon, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Price A, Smith JR, Mughal F, Salimi A, Melendez-Torres GJ, Newlove-Delgado T. Protocol for the mixed methods, Managing young people (aged 16-25) with Attention deficit hyperactivity disorder in Primary care (MAP) study: mapping current practice and co-producing guidance to improve healthcare in an underserved population. BMJ Open. 2023 Jul 10;13(7):e068184. doi: 10.1136/bmjopen-2022-068184.

Reference Type DERIVED
PMID: 37429692 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://sites.exeter.ac.uk/mapadhd/

Study website, with additional background information. Public facing, and hosted by Sponsor organisation (University of Exeter)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MHF008

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

313424

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.